KEEGO HARBOR, MI--(Marketwired - Nov 17, 2016) - ZIVO Bioscience, Inc. (OTCQB: ZIVO) unveiled a new, high-protein vegan power drink concept at the Company's annual shareholders meeting on November 9, 2016 in Detroit, Michigan.
The vegetable and fruit juice beverage contains a substantial amount of the Company's proprietary algal biomass, dried to a fine powder, that mixes well with other vegetable and fruit juices, while providing a significant non-animal, non-dairy, non-GMO vegan protein component. Early formulations boast a standout 42 grams of plant-based protein per 15-ounce serving.
The ZIVO algae biomass represents a viable alternative to other sources of high-quality protein. A 100- gram (3 oz.) portion provides 42 grams of protein and 24 grams of fiber, while also delivering more Vitamin C than a medium-sized orange and more Vitamin A than 3-1/2 ounces of beef liver.
Initially, this new product format will be focused on displacing other soy and whey-based powdered proteins -- a significant global market.
Unlike many other cultivated algae, the ZIVO strain is essentially bland and mixes well with sweet or savory flavors. The two flavors presented at the meeting featured a sweet, pomegranate finish, and the other a more savory vegetable finish.
The Company has recently concluded a series of nutritional, toxicological and microbial testing as the algal biomass enters the compliance phase of its market launch program. Product formulation concepts such as the protein power drink are useful for marketing the biomass as a viable protein enhancement ingredient, and to test for product stability, interactions and taste. The Company recently engaged a beverage consultant to assist in the formulation and testing of various product concepts.
Video clips featuring the Company's annual shareholder meeting, including the protein drink, have been posted to the newly-revamped Investors page of the ZIVO Bioscience corporate website:
About ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc. (OTCQB: ZIVO) is a Michigan-based biotech company engaged in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.